Regentis Biomaterials Ltd.
Sector: Healthcare & Life Sciences
About Regentis Biomaterials Ltd.
Tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue. (NYSE: RGNT)
Products
Gelrin
A patented hydrogel platform. It is a family of hydrogels that derive their unique physical and chemical properties from polymer chains crosslinked with trace quantities of denatured protein. In the body, Gelrin is eroded and resorbed over time through a pre-programmed and controlled gradual surface degradation process, meaning that the GelrinC implant covers the entire wound, so the cells that naturally want to migrate to the damaged tissue in situations where there is nothing holding them back or preventing them from migration, are unable to migrate due to the GelrinC implant and are controlled, which allows for the receding implant to allow the surrounding cells to regenerate the cartilage in a controlled and synchronous process.